MovDisordV3, Main, Exploration, bibRecord, 003A45

A pilot tolerability and efficacy trial of sodium oxybate in ethanol‐responsive movement disorders

Identifieur interne : 003A45 ( Main/Exploration ); précédent : 003A44; suivant : 003A46

A pilot tolerability and efficacy trial of sodium oxybate in ethanol‐responsive movement disorders

Auteurs : Steven J. Frucht [États-Unis] ; Yvette Bordelon [États-Unis] ; William H. Houghton [États-Unis] ; Dayton Reardan [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2005-10.

RBID : ISTEX:13DB9E68088F40250D33A2690DEBC082CC1E3214

Descripteurs français

Pascal (Inist)
- Ethanol, Myoclonie, Oxybate sodium, Système nerveux pathologie, Tremblement.

English descriptors

KwdEn :
- Adjuvants, Anesthesia (adverse effects), Adjuvants, Anesthesia (therapeutic use), Adult, Aged, Central Nervous System Depressants (adverse effects), Central Nervous System Depressants (therapeutic use), Drug Administration Schedule, Drug Therapy, Combination, Dystonia (diagnosis), Dystonia (drug therapy), Essential Tremor (diagnosis), Essential Tremor (drug therapy), Ethanol, Ethanol (adverse effects), Ethanol (therapeutic use), Female, Humans, Male, Myoclonus, Myoclonus (diagnosis), Myoclonus (drug therapy), Nervous system diseases, Pilot Projects, Severity of Illness Index, Sodium Oxybate (adverse effects), Sodium Oxybate (therapeutic use), Sodium oxybate, Treatment Outcome, Tremor, Xyrem, ethanol, myoclonus, sodium oxybate, tremor, γ‐hydroxybutyric acid.
MESH :
- chemical , adverse effects : Adjuvants, Anesthesia, Central Nervous System Depressants, Ethanol, Sodium Oxybate.
- chemical , therapeutic use : Adjuvants, Anesthesia, Central Nervous System Depressants, Ethanol, Sodium Oxybate.
- diagnosis : Dystonia, Essential Tremor, Myoclonus.
- drug therapy : Dystonia, Essential Tremor, Myoclonus.
- Adult, Aged, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Male, Pilot Projects, Severity of Illness Index, Treatment Outcome.

Abstract

Sodium oxybate is currently approved in the United States exclusively for the treatment of cataplexy in narcoleptic patients. In a prior article published in this journal, we reported a patient with severe posthypoxic myoclonus whose myoclonus improved with ethanol and also with treatment with sodium oxybate. We extend this preliminary observation to five other patients with ethanol‐responsive movement disorders in an open‐label, dose‐titration, add‐on, 8‐week trial. All five patients (one with severe alcohol‐responsive posthypoxic myoclonus, two with ϵ‐sarcoglycan–linked myoclonus–dystonia, and two with essential tremor) experienced improvement from baseline of 50% or greater as measured by blinded videotape review. Tolerability was satisfactory, with dose‐dependent sedation as the most common side effect. Further studies of this drug in hyperkinetic movement disorders are warranted. © 2005 Movement Disorder Society

Url:

https://api.istex.fr/document/13DB9E68088F40250D33A2690DEBC082CC1E3214/fulltext/pdf

DOI: 10.1002/mds.20605

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A pilot tolerability and efficacy trial of sodium oxybate in ethanol‐responsive movement disorders</title>
<author><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J." last="Frucht">Steven J. Frucht</name>
</author>
<author><name sortKey="Bordelon, Yvette" sort="Bordelon, Yvette" uniqKey="Bordelon Y" first="Yvette" last="Bordelon">Yvette Bordelon</name>
</author>
<author><name sortKey="Houghton, William H" sort="Houghton, William H" uniqKey="Houghton W" first="William H." last="Houghton">William H. Houghton</name>
</author>
<author><name sortKey="Reardan, Dayton" sort="Reardan, Dayton" uniqKey="Reardan D" first="Dayton" last="Reardan">Dayton Reardan</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:13DB9E68088F40250D33A2690DEBC082CC1E3214</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/mds.20605</idno>
<idno type="url">https://api.istex.fr/document/13DB9E68088F40250D33A2690DEBC082CC1E3214/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001F70</idno>
<idno type="wicri:Area/Istex/Curation">001F70</idno>
<idno type="wicri:Area/Istex/Checkpoint">002455</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Frucht S:a:pilot:tolerability</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15986420</idno>
<idno type="wicri:Area/PubMed/Corpus">003016</idno>
<idno type="wicri:Area/PubMed/Curation">003016</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003257</idno>
<idno type="wicri:Area/Ncbi/Merge">001296</idno>
<idno type="wicri:Area/Ncbi/Curation">001296</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001296</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Frucht S:a:pilot:tolerability</idno>
<idno type="wicri:Area/Main/Merge">005132</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:06-0000276</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001D42</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000F79</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001F52</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Frucht S:a:pilot:tolerability</idno>
<idno type="wicri:Area/Main/Merge">005430</idno>
<idno type="wicri:Area/Main/Curation">003A45</idno>
<idno type="wicri:Area/Main/Exploration">003A45</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A pilot tolerability and efficacy trial of sodium oxybate in ethanol‐responsive movement disorders</title>
<author><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J." last="Frucht">Steven J. Frucht</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Columbia University Medical Center, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bordelon, Yvette" sort="Bordelon, Yvette" uniqKey="Bordelon Y" first="Yvette" last="Bordelon">Yvette Bordelon</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Columbia University Medical Center, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Houghton, William H" sort="Houghton, William H" uniqKey="Houghton W" first="William H." last="Houghton">William H. Houghton</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Orphan Medical, Inc., Minnetonka, Minnesota</wicri:regionArea>
<placeName><region type="state">Minnesota</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Reardan, Dayton" sort="Reardan, Dayton" uniqKey="Reardan D" first="Dayton" last="Reardan">Dayton Reardan</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Orphan Medical, Inc., Minnetonka, Minnesota</wicri:regionArea>
<placeName><region type="state">Minnesota</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2005-10">2005-10</date>
<biblScope unit="vol">20</biblScope>
<biblScope unit="issue">10</biblScope>
<biblScope unit="page" from="1330">1330</biblScope>
<biblScope unit="page" to="1337">1337</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">13DB9E68088F40250D33A2690DEBC082CC1E3214</idno>
<idno type="DOI">10.1002/mds.20605</idno>
<idno type="ArticleID">MDS20605</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Anesthesia (adverse effects)</term>
<term>Adjuvants, Anesthesia (therapeutic use)</term>
<term>Adult</term>
<term>Aged</term>
<term>Central Nervous System Depressants (adverse effects)</term>
<term>Central Nervous System Depressants (therapeutic use)</term>
<term>Drug Administration Schedule</term>
<term>Drug Therapy, Combination</term>
<term>Dystonia (diagnosis)</term>
<term>Dystonia (drug therapy)</term>
<term>Essential Tremor (diagnosis)</term>
<term>Essential Tremor (drug therapy)</term>
<term>Ethanol</term>
<term>Ethanol (adverse effects)</term>
<term>Ethanol (therapeutic use)</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Myoclonus</term>
<term>Myoclonus (diagnosis)</term>
<term>Myoclonus (drug therapy)</term>
<term>Nervous system diseases</term>
<term>Pilot Projects</term>
<term>Severity of Illness Index</term>
<term>Sodium Oxybate (adverse effects)</term>
<term>Sodium Oxybate (therapeutic use)</term>
<term>Sodium oxybate</term>
<term>Treatment Outcome</term>
<term>Tremor</term>
<term>Xyrem</term>
<term>ethanol</term>
<term>myoclonus</term>
<term>sodium oxybate</term>
<term>tremor</term>
<term>γ‐hydroxybutyric acid</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adjuvants, Anesthesia</term>
<term>Central Nervous System Depressants</term>
<term>Ethanol</term>
<term>Sodium Oxybate</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adjuvants, Anesthesia</term>
<term>Central Nervous System Depressants</term>
<term>Ethanol</term>
<term>Sodium Oxybate</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dystonia</term>
<term>Essential Tremor</term>
<term>Myoclonus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term>
<term>Essential Tremor</term>
<term>Myoclonus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Drug Administration Schedule</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Pilot Projects</term>
<term>Severity of Illness Index</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Ethanol</term>
<term>Myoclonie</term>
<term>Oxybate sodium</term>
<term>Système nerveux pathologie</term>
<term>Tremblement</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Sodium oxybate is currently approved in the United States exclusively for the treatment of cataplexy in narcoleptic patients. In a prior article published in this journal, we reported a patient with severe posthypoxic myoclonus whose myoclonus improved with ethanol and also with treatment with sodium oxybate. We extend this preliminary observation to five other patients with ethanol‐responsive movement disorders in an open‐label, dose‐titration, add‐on, 8‐week trial. All five patients (one with severe alcohol‐responsive posthypoxic myoclonus, two with ϵ‐sarcoglycan–linked myoclonus–dystonia, and two with essential tremor) experienced improvement from baseline of 50% or greater as measured by blinded videotape review. Tolerability was satisfactory, with dose‐dependent sedation as the most common side effect. Further studies of this drug in hyperkinetic movement disorders are warranted. © 2005 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Minnesota</li>
<li>État de New York</li>
</region>
</list>
<tree><country name="États-Unis"><region name="État de New York"><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J." last="Frucht">Steven J. Frucht</name>
</region>
<name sortKey="Bordelon, Yvette" sort="Bordelon, Yvette" uniqKey="Bordelon Y" first="Yvette" last="Bordelon">Yvette Bordelon</name>
<name sortKey="Houghton, William H" sort="Houghton, William H" uniqKey="Houghton W" first="William H." last="Houghton">William H. Houghton</name>
<name sortKey="Reardan, Dayton" sort="Reardan, Dayton" uniqKey="Reardan D" first="Dayton" last="Reardan">Dayton Reardan</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A45 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003A45 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:13DB9E68088F40250D33A2690DEBC082CC1E3214
   |texte=   A pilot tolerability and efficacy trial of sodium oxybate in ethanol‐responsive movement disorders
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

A pilot tolerability and efficacy trial of sodium oxybate in ethanol‐responsive movement disorders

A pilot tolerability and efficacy trial of sodium oxybate in ethanol‐responsive movement disorders

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.